[Treatment problems using anabolic steroids in progressive muscular dystrophy].
D000293:Adolescent; D000328:Adult; D045930:Anabolic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D000818:Animals; D002648:Child; D002675:Child, Preschool; D045166:Estradiol Congeners / Q000627:therapeutic use; D005260:Female; D013006:Growth Hormone / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008695:Methandriol / Q000627:therapeutic use; D008696:Methandrostenolone / Q000627:therapeutic use; D008777:Methyltestosterone / Q000627:therapeutic use; D008875:Middle Aged; D009124:Muscle Proteins / Q000096:biosynthesis; D009132:Muscles / Q000187:drug effects / Q000378:metabolism; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D009137:Muscular Dystrophy, Animal / Q000188:drug therapy / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D013739:Testosterone / Q000627:therapeutic use; D014158:Transcription, Genetic / Q000187:drug effects
D045930:Anabolic Agents; D045166:Estradiol Congeners; D009124:Muscle Proteins; D013739:Testosterone; D008695:Methandriol; D013006:Growth Hormone; D008696:Methandrostenolone; D008777:Methyltestosterone
Voprosy lecheniia progressiruiushcheĭ myshechnoĭ distrofii anabolicheskimi steroidami.